title: Pharmacoeconomic evaluation in Ireland: a review of the process.
abstract: To describe the pharmacoeconomic assessment process in Ireland and to provide examples of recent appraisals and the subsequent impact on pricing and reimbursement decisions. The pharmacoeconomic appraisals conducted by the National Centre for Pharmacoeconomics (NCPE) between September 2006 and February 2009 were reviewed. The NCPE recommendations and subsequent reimbursement decisions by the Health Service Executive (HSE) were recorded. Recommendations made by the NCPE were compared with those of UK agencies. The duration of the NCPE pharmacoeconomic process and the time from marketing authorization to reimbursement was estimated. The budget impact assessments from the pharmaceutical companies were reviewed and compared for consistency. The NCPE conducted 12 single technology appraisals during the study period. Eight of the medicines assessed were either recommended as a cost-effective use of resources or recommended with certain restrictions, and were funded by the HSE. Of the four medicines that were not considered cost effective, two were reimbursed after a price reduction was negotiated and the remaining two were not. The NCPE recommendations concurred with those of the UK agencies for the majority of appraisals, with the exception of sunitinib and lapatinib. The average duration of the NCPE process was 2.7 months. The average time from marketing authorization to reimbursement was 7 months. The review of budget impact assessments highlighted a high degree of variability between submissions. The findings of this review highlight the efficiency of the pharmacoeconomic process and the acceptance of the NCPE recommendations by the HSE for pricing and reimbursement decisions. NCPE recommendations broadly concurred with those of UK agencies for the majority of appraisals.
authors.affiliation: National Centre for Pharmacoeconomics, St James's Hospital, James's Street, Dublin 8, Ireland. ltilson@stjames.ie
authors.forename: Lesley
authors.initials: L
authors.lastname: Tilson
authors.forename: Aisling
authors.initials: A
authors.lastname: O'Leary
authors.forename: Cara
authors.initials: C
authors.lastname: Usher
authors.forename: Michael
authors.initials: M
authors.lastname: Barry
mesh_terms: D003362:Cost-Benefit Analysis / Q000458:organization & administration; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D019981:Health Care Sector / Q000458:organization & administration; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000191:economics*; D007356:Insurance, Pharmaceutical Services / Q000191:economics; D007494:Ireland; D009313:National Health Programs / Q000458:organization & administration*; D055553:Prescription Drugs / Q000191:economics*
chemical_list: D055553:Prescription Drugs